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ABSTRACT
Myeloablative chemotherapy or radiation therapy supported by autologous stem cell transplantation (SCT) for the
treatment of hematologic malignancies such as acute leukemia, lymphoma, and myeloma is associated with high
rates of relapse. The reasons for this are 1) autologous transplantation lacks the in vivo graft-vs.-tumor (GVT) effect
associated with allogeneic SCT, which is effective in controlling or eliminating residual malignant cells remaining in
the body after high-dose therapy, and 2) contaminating malignant cells in the autologous graft are reinfused into the
body. Some researchers have attempted to administer immunomodulatory cytokines to simulate a GVT effect, and
although this has shown some efficacy, it has several disadvantages. These include high toxicity associated with sys-
temic administration, a short in vivo half-life, and insufficient levels reaching the site of residual disease. As an alter-
native, we investigated whether delivery of the cytokine interleukin (IL)-2 to the bone marrow can exert an
antileukemic effect while avoiding the problems associated with systemic administration. We describe the delivery
of IL-2 to the bone marrow by transplantation of syngeneic bone marrow, retrovirally transduced with the gene for
IL-2, into lethally irradiated mice. We were able to efficiently transduce murine bone marrow with the IL-2 gene
without adversely affecting clonogenic output from hematopoietic progenitors, and we were able to achieve expres-
sion of the transgene in transplanted animals. However, IL-2 transduction inhibited hematopoietic reconstitution in
lethally irradiated mice. Marrow transduced with high-titer, high-expressing IL-2 retrovirus failed to engraft, and a
low-titer, low-expressing IL-2 retrovirus also demonstrated reduced engraftment, although engraftment was suffi-
cient to support survival of transplanted mice. Long-term, low-level expression of the IL-2 transgene was detectable
in these mice and was effective in exerting an antileukemic effect. Mice transplanted with control marrow and chal-
lenged with leukemic cells suffered 100% mortality within 70 days, whereas mice transplanted with IL-2–trans-
duced marrow exhibited 50% survival over the 175-day duration of this study. The work shows that delivery of
immunomodulatory cytokines to the bone marrow can be achieved by transplantation of genetically modified
hematopoietic cells. Furthermore, low-level IL-2 expression can exert an antileukemic effect. These data suggest
that this may be an effective immunotherapeutic strategy to reduce relapse after autologous transplantation, but the
selection and expression of the cytokine must be carefully considered to minimize adverse effects on hematopoiesis. 
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INTRODUCTION
For patients with hematologic malignancies, SCT after
high-dose myeloablative therapy has improved disease-free
outcome compared with that of conventional chemotherapy.
For example, 50–70% of patients suffering from acute
myleloid leukemia (AML) or acute lymphoblastic leukemia
(ALL) remain disease free after allogeneic SCT from a
genotypically matched sibling or unrelated donor [1,2],
whereas only 25% have a durable clinical remission with
conventional chemotherapy [3,4]. Unfortunately, suitable
donors are not available for most patients; furthermore,
allogeneic SCT is associated with the occurrence of graft-
vs.-host disease (GVHD) that has limited allogeneic SCT to
patients who are <50–55 years of age [5].
One alternative to unmanipulated allogeneic SCT is the
depletion of T lymphocytes from an allogeneic stem cell
graft to alleviate the problem of GVHD [6,7]. Another
alternative, which also addresses the shortage of suitable
donors, is the use of autologous transplantation in which the
patient serves as his or her own donor [8,9]. Unfortunately,
although these strategies effectively eliminate GVHD, both
result in dramatic increases in posttransplant relapse in spite
of work to improve pretransplant chemotherapy and ex vivo
purging of autologous marrow cells [6,7,10–12]. 
Two factors appear to be responsible for the higher
relapse rate seen in autologous SCT. First, autologous stem
cells, even when harvested during clinical remission, contain
enough residual leukemic cells to reestablish the disease
[13]. Second, high-dose therapy is not able to completely
eliminate malignant cells from the patient, and these resid-
ual cells, known as minimal residual disease, can ultimately
lead to relapse. In allogeneic transplantation, T lymphocytes
present in the donor cells are crucial in inducing a cascade
of antitumor effects that have been collectively termed the
graft-vs.-tumor (GVT) effect [12,14,15]. They recognize
the minor histocompatibility antigens on recipient cells,
undergo clonal expansion, and release a number of
cytokines, most notably IL-2 [16]. This, in turn, stimulates
production of tumor necrosis factor (TNF)-a and interferon
(IFN)-g by monocytes, T lymphocytes, and natural killer
(NK) cells [17]. GVT is effective in controlling or eliminat-
ing the minimal residual disease. GVT is not associated with
autologous or allogeneic T cell–depleted transplantation,
which eliminates the afferent arm of the alloimmune
response and prevents the occurrence of a number of sec-
ondary antileukemic effector mechanisms such as the release
of immunomodulatory cytokines.
Therefore, a major problem in achieving long-term dis-
ease-free survival with SCT, particularly after autologous or
allogeneic T cell–depleted SCT, is disease relapse from
malignant cells remaining after high-dose therapy. One
strategy to reduce relapse is to mimic GVT effects through
the administration of cytokines after autologous or allogene-
ic T cell–depleted SCT [18–20]. Treatment with IL-2 and
IFN-g has shown some success in preventing relapse, but
systemic administration of these cytokines can have substan-
tial side effects, especially when the cytokines are given in
the first few weeks after SCT. Furthermore, these cytokines
have a short effective life in the circulation, and it is unclear
if sufficiently high concentrations reach the site of residual
disease in the marrow. 
Here we describe preliminary work investigating
whether localized delivery of the immunomodulatory
cytokine IL-2, by transplantation of progenitor cells geneti-
cally transduced with the IL-2 gene, can exert an
antileukemic effect after autologous transplantation. We
describe the retroviral transduction of murine BM with the
gene for murine IL-2 and examine the effect of IL-2 trans-
fection on transplantation and engraftment of lethally irra-
diated mice. Furthermore, we test whether IL-2–transfected
BM is able to exert an antileukemic effect in syngeneically
transplanted mice and improve survival in a murine myeloid
leukemia model. In this work, we were able to efficiently
transfect murine BM with IL-2, and detectable levels of IL-
2 were found in both the supernatant of transfected cells
and the serum of mice transplanted with these BM cells.
However, high levels of IL-2 expression were found to com-
promise BM engraftment in a dose-dependent manner.
Long-term IL-2 expression was seen in mice transplanted
with BM transfected with a low titer/low IL-2–expressing
retrovirus that allowed sufficient engraftment for long-term
survival. In these mice, transplantation of IL-2–transduced
marrow did exert an antileukemic effect that was effective in
controlling or eliminating a leukemic challenge. Mice trans-
planted with IL-2–transfected marrow and challenged with
a myeloid leukemia cell line displayed a significantly
increased life span over those transplanted with either
untransfected BM or marrow transfected with a control vec-
tor. These data suggest that cytokine delivery to BM is able
to exert an antileukemic effect and may be a suitable treat-
ment strategy to control or eliminate minimal residual dis-
ease and reduce the incidence of relapse after autologous
SCT. However, the choice of cytokine and expression
parameters must be carefully evaluated to avoid adverse
effects on hematopoietic reconstitution.
MATERIALS AND METHODS
Cells and cell lines
The murine AML cell line MMB3.19 (a generous gift
from R. Korngold, Kimmel Cancer Institute, Jefferson
Medical College, Philadelphia, PA [21]) was maintained in
RPMI 1640 supplemented with 5% fetal calf serum (FCS).
NIH 3T3 cells were cultured in RPMI with 10% calf serum.
The retroviral packaging cell line GP+E86 was obtained
from K. Humphries (Terry Fox Laboratory, Vancouver, BC,
Canada). Cells were selected in Dulbecco’s modified Eagle’s
medium (DMEM) containing newborn calf serum (NBCS)
with hypoxanthine, xanthine, and mycophenolic acid and
maintained in DMEM supplemented with 10% NBCS. All
media were obtained from Stem Cell Technologies (Vancou-
ver). Serum was obtained from Hyclone (Logan, UT) and
heat-inactivated at 56oC for 0.5 hour before use. 
Animals
Eight- to 12-week-old C57BL/6 male mice were used in
these experiments. Mice were either obtained directly or
were bred from parental strain breeders originally obtained
from the Jackson Laboratory (Bar Harbor, ME). Animals
were housed in microisolator cages and maintained with
sterilized food and acidified water in the animal facility of
the British Columbia Cancer Research Center. 
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Leukemic challenge
To determine an appropriate dose of leukemic cells at
which to challenge the mice, C57BL/6 mice were exposed
to varying doses of the MMB3.19 leukemic cell line. Mice
were lethally irradiated with 900 cGy total-body irradia-
tion using a cesium source at a dose rate of 1.45 cGy/min
and transplanted by intravenous injection of 23106 syn-
geneic BM cells in a volume of 0.2 mL RPMI with 2%
FCS into the lateral tail vein. Mice were then challenged
with 0, 104, 105, 106, and 107 MMB3.19 cells. MMB3.19
cells were collected by brief trypsinization and resuspend-
ed in a volume of 0.5 mL RPMI with 2% FCS for
intraperitoneal injection. Mice were monitored for survival
and subjected to postmortem examination. From these
experiments, a dose of 104 MMB3.19 cells was selected for
subsequent leukemic challenges, which were administered
as described above.
Vector construction
The cDNA for murine IL-2 was isolated by reverse
transcription-polymerase chain reaction (RT-PCR) of RNA
isolated from murine T lymphocytes stimulated with phyto-
hemagglutinin (PHA) and subcloned into Kpn I and Xba I
sites of pUC19. To generate the retroviral vector MSCV-
hIL2.PGK-neo, a Xba I (blunted)/Eco RI fragment contain-
ing the murine IL-2 gene from the pUC19-mIL-2 vector
was inserted into the Hpa I-Eco RI sites of the MSCV.PGK-
neo retroviral vector (provided by K. Humphries, Terry Fox
Laboratory). The retroviral vector Jzen-mIL2.TK-neo (pro-
vided by T. Kuhr, University Hospital, Innsbruck, Austria)
was generated by inserting the Kpn I-Xba I fragment con-
taining the mIL-2 into the complementary restriction sites
of the pTZ19RTK-neo vector. A cassette containing the IL-
2 gene and the TK-neo resistance gene was isolated by Sma
I/Hin DIII digestion and inserted into the Hpa I/Hin DIII
sites of the Jzen.1 retroviral backbone. As a control vector,
the MSCV.PGK-neo with no insert was used. 
Retroviral generation and transduction of murine BM
To generate infectious retroviral particles, DNA vectors
containing MSCV-mIL2.PGK-neo, Jzen-mIL2.TK-neo,
and MSCV.PGK-neo were introduced into the ecotropic
packaging cell line GP+E86 by calcium-phosphate precipi-
tation. Transfected cells were grown under selection with
the neomycin analog G418 (Life Technologies, Burlington,
ON). Isolated colonies representing individual clones of
retroviral producer cells were isolated for the MSCV-
mIL2.PGK-neo and Jzen-mIL2.TK-neo vectors and
assayed for retroviral titer on the basis of their ability to
infect and generate G418-resistant NIH-3T3 cells. High-
titer clones were selected and expanded. For the
MSCV.PGK-neo control vector, a polyclonal producer pop-
ulation was used. 
For retroviral transduction of murine BM, 7- to 12-week-
old donor mice were injected with 150 mg/kg body weight of
5-fluorouracil 4 days before harvest. Mice were killed, and
BM cells were collected by flushing the marrow cavities of the
femur and tibia with a-minimal essential medium (a-MEM)
supplemented with 2% FCS. Cells were collected, enumerat-
ed, and prestimulated by culturing for 48 hours at a concen-
tration of 1–53105 cells/mL in DMEM with 15% FCS, 6
ng/mL mIL-3, 100 ng/mL mSF, and 10 ng/mL hIL-6. Cells
were infected by coculture with the viral producer cells. For
coculture, the viral producer cells were cultured in DMEM
with 10% NBCS until they were 70% confluent. Producer
cells were irradiated with 1500 cGy using an X-ray machine
(Model RT250, Philips, Amsterdam), and BM cells were
added at a concentration of 2–43106 cells in medium con-
taining 6 ng/mL IL-3, 10 ng/mL IL-6, and 100 ng/mL SF
with 6 ng/mL polybrene. Cells were cocultured with the pro-
ducer cells for 48 hours with one medium change before BM
cells were carefully harvested. 
To determine transduction efficiency and the effect of
IL-2 transduction on clonogenic output, 2000 to 10,000
cells were plated in methycellulose with growth factors to
support detection of murine myeloid (MethoCult GF
M3434) and pre-B lymphoid (MethoCult M3630) clono-
genic hematopoietic progenitor cells in culture dishes
(Greiner, GmbH, Frickenhausen, Germany) with or without
G418 (1.2 mg/mL active weight). Colonies were enumerat-
ed 12 to 14 days later using an inverted phase-contrast
microscope and classified on the basis of morphology and
cell number into BFU-E (burst-forming unit-erythrocyte),
CFU-GM (colony-forming unit-granulocyte/macrophage),
and CFU-GEMM (CFU-erythrocyte, granulocyte, macro-
phage, and megakaryocyte) colonies. 
Transplantation and documentation of engraftment
Recipient mice were lethally irradiated with 900 cGy
and transplanted with 33105 retrovirally transduced BM
cells in a volume of 0.1 mL. Engraftment of recipient mice
was documented by enumeration of nucleated cells in the
marrow and spleen of transplanted mice. For BM, cells from
the tibia and fibia were harvested by flushing the marrow
cavity with a-MEM with 2% FCS. For enumeration of
splenic cells, spleens were removed, minced, and dissociated
by passage through a cell strainer (Falcon, Franklin Lakes,
NJ). Erythrocytes were lysed with 3% acetic acid solution,
and nucleated cells were stained with methylene blue and
counted. 
The effect of IL-2 transduction on hematopoietic pro-
genitor cells in transplanted mice was examined using a
CFU assay performed on BM cells isolated from mice trans-
planted with control and IL-2–transduced marrow. Marrow
was collected on days 14, 50, and 100 posttransplantation,
counted, and plated in methycellulose in the presence or
absence of G418. Colonies were counted 14 days later under
an inverted microscope. To enumerate CFU-S (CFU-
spleen), transplanted mice were killed on day 12, and
spleens were excised and examined macroscopically for dis-
tinct colonies on the surface.
IL-2 production
The production of murine IL-2 from transduced BM in
the serum of transplanted mice and in the supernatant of cul-
tured marrow cells was determined by enzyme-linked
immunosorbent assay (ELISA) (Cytoscreen mIL-2 ELISA,
BioSource International, Montreal, Quebec, Canada) con-
sisting of anti–mIL-2 primary antibody, a biotinylated sec-
ondary antibody, and a streptavidin-horseradish peroxidase
conjugate. This is a colorimetric assay based on conversion
of tetramethylbenzidine substrate by the peroxidase enzyme.
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The assay is quantitated by absorbance at 450 nm. For serum
determination, blood was collected on days 14, 20, 50, and
100 posttransplant by cardiac puncture and allowed to clot.
Serum was collected by centrifuging the clotted blood and
removing the supernatant. For cell supernatants, cells were
cultured in IL-2–free medium under appropriate conditions
for 24 hours. Supernatant was collected by centrifugation.
RESULTS
Animal model
To establish an animal model for AML in which to test
our hypothesis, we used the murine AML cell line MMB3.19
[21]. The line was raised in a C57BL/6 background by retro-
viral transfection of the c-myc gene, express normal myeloid
differentiation markers including Mac-1, Mac-2, F4/80, and
LFA-1, and are similar to spontaneous tumors in their
expression of c-myc and the accumulation of spontaneous
secondary mutations. To determine their activity and to
establish a suitable challenge dose, lethally irradiated, syn-
geneically transplanted C57BL/6 mice were challenged with
104 to 107 cells. These doses resulted in 100% mortality
within 30 days in all groups. As shown in the dose-response
assay (Fig. 1), the number of leukemic cells had a direct
inverse relationship on survival, as expected. Mice challenged
with doses of 104, 105, 106, and 107 had average survival times
of 24 days (median 23.5), 18 days (median 17.5), 13.6 days
(median 16.5), and 8 days (median 8), respectively. All of the
control, unchallenged mice survived for the entire length of
the experiments (60 days). Based on these results, a dose of
104 cells was selected for use in all subsequent experiments. 
To confirm that these cells are sensitive to IL-2–activat-
ed killing, MMB3.19 cells were tested for sensitivity to NK
cell and lymphokine-activated killer (LAK) cell activity.
Spleens were isolated from mice, dissociated to single cells,
and tested for their ability to kill the MMB3-19 cells before
or after a 4-day activation with 500 U/mL of IL-2. As
shown in Fig. 2, unactivated spleen cells exhibited no
detectable killing of the leukemic cells in a standard chromi-
um release assay. After activation with IL-2, however, the
spleen cells were found to have cytolytic activity against
MMB3.19 cells. Yac-1 (NK- and LAK-sensitive) and P815
(NK-resistant, LAK-sensitive) cell lines were used as con-
trols for this experiment (data not shown). Based on these
data, we concluded that the combination MMB3.19-
C57BL/6 mice provided a suitable model system in which to
perform these experiments.
Retroviral transduction of murine BM
For retroviral transduction of murine BM, clones of the
retroviral producers for MSCV-mIL2.PGK-neo and Jzen-
mIL2.TK-neo in GP+E86 packaging cells were isolated and
screened for high titer retrovirus–producing clones by their
ability to generate neomycin-resistant NIH 3T3 clones.
MSCV-mIL2.PGK-neo and Jzen-mIL2.TK-neo producers
with titers of 4.63105 and 1.43105 CFU/mL, respectively,
Figure 1. Dose response of C57BL/6 mice challenged with the
leukemic cell line MMB3.19
C57BL/6 mice were lethally irradiated with 850 cGy of total body irradiation
and transplanted with syngeneic BM. Mice were challenged with 104 (white
circles), 105 (white triangles), 106 (white squares), and 107 (white diamonds)
MMB3.19 leukemic cells intravenously and monitored for survival in com-
parison with control mice (irradiated and transplanted; black diamonds). Sur-
vival was inversely proportional to the dose of leukemic cells. Mice challenged
with 104 cells had an average survival of 24 days with a 23.5 day median.
Mice challenged with 105 cells survived an average of 18 days and had a 17.5
day median survival. Mice challenged with 106 cells had an average survival
of 13.6 days and a median survival of 16.5 days, whereas those challenged
with 107 cells had an average and median survival of 8 days. Control mice
(irradiated and transplanted but not challenged) survived the entire length of
the study (60 days). 
Figure 2. NK- and LAK-mediated killing of the leukemic cell line
MMB3.19
A standard 4-hour chromium-51 release assay was used to determine if the
leukemic cell line MMB3.19 was susceptible to either NK- or LAK-mediated
killing. Spleens were excised from C57BL/6 mice and dissociated to single
cells. Spleen cells were tested for their ability to kill 51Cr-labeled MMB3.19
cells in a 4-hour in vitro assay at effector:target ratios ranging from 50:1 to
5:1. Cells were tested either immediately after isolation for sensitivity to NK-
mediated killing (white bars) or after a 4-day stimulation with 500 U/mL of
IL-2 for sensitivity to LAK-mediated killing (black bars). MMB3.19 cells
were not killed by freshly isolated spleen cells. However, after stimulation with
IL-2, spleen cells were able to cytolyse the leukemic cells (16-3% at
effector:target ratios of 50:1 to 5:1).
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were selected and expanded for subsequent experiments.
These cells were checked periodically for replication-com-
petent helper virus by testing of the supernatant of infected
NIH 3T3 cells. 
To confirm that selected producer cells possessed a
retroviral backbone with an intact mIL-2 cDNA coding
sequence, the expression and synthesis of the mIL-2 gene
and protein from these cells were assayed by Northern blot
analysis (data not shown) and ELISA, respectively. Both the
MSCV-mIL2.PGK-neo and Jzen-mIL2.TK-neo producer
cells were found to express and synthesize mIL-2 (1.49 and
0.834 ng/106 cells/24 hours, respectively). As a control, a
polyclonal MSCV.PGK-neo producer population with a
retroviral titer of 2.63105 was used. IL-2 was detected at
background levels in these neo-transduced marrow cells.
To determine their ability to transduce BM, these retro-
viruses were used to infect murine BM by coculture, and the
transduction efficiency was determined by plating the BM in
methylcellulose-containing medium in the presence and
absence of the neomycin analog G418. Transduction effi-
ciency (Table 1) was expressed as the percentage of hemato-
poietic colonies that developed in the presence of G418
compared with the total number of colonies. Efficiency was
directly related to retroviral titer, with MSCV-mIL2.PGK-
neo transducing up to 55–80% of BM cells. The lower
retroviral titer of Jzen-mIL2.TK-neo was reflected in its
10–37% transduction efficiency, whereas MSCV.PGK-neo
exhibited both an intermediate titer and a transduction effi-
ciency of 23–29%.
Several variables were examined to characterize the
transduction of the murine BM cells with the IL-2 gene
using these vectors. Transduction with IL-2 did not appear
to affect progenitor cells adversely, as judged by an in vitro
CFU assay. The in vitro colony-forming potential of the IL-
2–transduced BM progenitor cells was not adversely affected
in cells transfected with either MSCV-mIL2.PGK-neo or
Jzen-mIL2.TK-neo compared with MSCV.PGK-neo in
terms of either total colony number (374.00 ± 80.4, 242.50 ±
17.7, and 271.25 ± 89.6, respectively from 13104 input cells)
or proportion of different colony types (Fig. 3). The num-
ber of CFU-GM colonies ranged between 79 and 85% of
total, BFU-E colonies were between 12 and 17%, and
CFU-GEMM colonies were between 3 and 5%, which is in
agreement with average values of 60–100% for CFU-GM,
8–24% for BFU-E, and 5–14% for CFU-GEMM. 
To determine if early progenitor cells were transfected
with the IL-2 gene under these conditions, untransfected
cells and MSCV-mIL2.PGK-neo, Jzen-mIL2.TK-neo, and
MSCV.PGK-neo transfected cells were used to initiate Dex-
ter long-term cultures (LTC) [22,23]. Marrow was plated
onto irradiated murine stromal cells in long-term medium
and subjected to half medium changes each week. IL-2
transfected cells appeared to exert a toxic effect on the LTC
stromal cells, however. The stromal layer of cultures of
untransduced or transduced control cells were maintained
and appeared normal, whereas the stromal layer of LTCs
initiated with MSCV-IL2.PGK-neo or (to a lesser extent)
Jzen-IL2.TK-neo transduced marrow detached and died
during culture.
To determine if the retrovirally transduced gene was
preferentially expressed in myeloid or lymphoid lineages,
infected BM cells were cultured under Dexter or Witte con-
ditions, which favor myeloid or lymphoid cells, respectively.
Supernatants from these cultures were collected and ana-
lyzed for IL-2 production by ELISA. In both MSCV-
mIL2.PGK-neo and Jzen-mIL2.TK-neo transduced mar-
row cultured under Dexter conditions, IL-2 levels were ini-
tially high and declined rapidly but remained above back-
ground. Under Witte conditions, initial IL-2 production
Table 1. Efficiency of retrovirus transduction of murine bone marrow
Retrovirus Titer* Efficiency†
MSCV-mIL2.PGK-neo 4.63105 CFU/mL 66.71 6 9.16%
Jzen-mIL2.TK-neo 1.43105 CFU/mL 19.13 6 9.37%
MSCV.PGK-neo 2.63105 CFU/mL 25.50 6 3.00%
*We determined the titers of retroviral producer clones for MSCV-
mIL2.PGK-neo, Jzen-mIL2.TK-neo, and MSCV.PGK-neo by measuring
their ability to infect NIH 3T3 cells and produce G418-resistant clones.
†We determined the ability of retrovirus to transduce murine BM by infecting
BM isolated from 5-fluorouracil–treated mice. Marrow was prestimulated for
48 hours with IL-3, IL-6, and FCS and infected by coculture with irradiated
viral producer cells for 48 hours with the cytokine cocktail and polybrene as
described in “Materials and Methods.” Efficiency was determined by plating
infected marrow in methycellulose in the presence (retrovirally infected) and
absence (total colonies) of G418. Efficiency is expressed as the percentage of
hematopoietic colonies that developed in the presence of G418 compared with
total number of colonies.
Figure 3. Relative proportion of CFU-G, BFU-E, and CFU-GEMM clono-
genic cells in untransduced and retrovirally transduced marrow
BM was isolated from 5-fluorouracil–treated C57BL/6 mice and retrovirally
transduced by coculture with retroviral producer cells for MSCV-mIL2.PGK-
neo, Jzen-mIL2.TK-neo or MSCV.PGK-neo for 2 days. Transduced and
untransduced control BM was plated in methylcellulose at 2 x 103 or 1 x 104
cells for 12 to 14 days. Colonies were enumerated using an inverted phase-con-
trast microscope and classified into CFU-GM (white bars), BFU-E (black bars),
or CFU-GEMM (cross-hatched bars) colony types on the basis of morphology. 
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was also very high but rapidly declined to background levels.
These results suggest that the myeloid cells were either
preferentially infected by the retroviruses, the retroviral
transgene was preferentially expressed in myeloid over lym-
phoid cells, or the IL-2 transgene adversely affected trans-
fected lymphoid cells. 
Transplantation of retrovirally transduced BM to lethally
irradiated mice
We assessed the ability of retrovirally transduced BM to
engraft syngeneic mice. C57BL/6 mice were irradiated with
900 cGy and transplanted with one of the following: 1)
untransduced BM (these mice formed the untransduced con-
trol group), 2) BM that had been transduced with MSCV-
mIL2.PGK-neo (100% MSCV-mIL2), 3) MSCV-
mIL2.PGK-neo transduced BM mixed 1:1 with untrans-
duced BM (50% MSCV-mIL-2), 4) BM that had been trans-
duced with Jzen-mIL2.TK-neo (Jzen-mIL2), and 5) BM that
had been transduced with the control MSCV.PGK-neo vec-
tor (these mice formed the transfected control group).
Expression of the transgene in transplanted mice was
assayed by ELISA. Levels of IL-2 in the serum of mice
transplanted with retrovirally transduced BM were assayed
at 14, 20, 50, and 100 days posttransplant (Table 2). Mice
transplanted with 100 or 50% MSCV-mIL2–transduced BM
had high levels of mIL-2 in their serum at both day 14 and
day 20 posttransplant, although levels declined rapidly. Mice
transplanted with Jzen-mIL2–transduced marrow had
slightly elevated levels of IL-2 in their serum, which persist-
ed up to 100 days posttransplant. Mice transplanted with
either untransfected control BM or MSCV-neo–transfected
BM had background levels. 
While documenting engraftment of retrovirally trans-
duced BM, we observed that mice transplanted with IL-
2–transduced BM had reduced life spans compared with
mice transplanted with either the untransduced or trans-
duced control marrow (Fig. 4). Mice transplanted with
untransduced marrow had 100% survival over the 100-day
term of this study. Similarly, mice transplanted with marrow
transduced with the MSCV-neo vector also exhibited 100%
survival over the 100-day period. In contrast, mice trans-
planted with marrow transduced with the high titer MSCV-
mIL2 all showed 100% mortality within 30 days. Those
transplanted with 100% transduced marrow had an average
survival of 21.7 days, with a median of 23 days, whereas
those transplanted with 50% transduced marrow had an
average survival of 25.3 days with a median of 28 days. Jzen-
mIL2–transduced marrow, when transplanted to lethally
irradiated mice, also exhibited reduced survival, although
most mice survived the length of the study (67% survival
rate over 100 days; 33% mortality at approximately day 27).
These data indicated that the IL-2 transgene had an adverse
effect on the transplanted animals. 
To determine the basis of this reduced survival rate,
transplanted mice were analyzed for engraftment and
hematopoietic reconstitution. Preliminary macroscopic
examination of these mice suggested that they were anemic,
with both blood and liver being lighter in color than blood
and liver of control mice. Further characterization indicated
an overall hypocellularity of the hematopoietic system. Mice
transplanted with IL-2–transduced marrow had reduced
marrow (Fig. 5A), spleen (Fig. 5B), and peripheral blood
(data not shown) cellularity compared with control mice
transplanted with control, untransduced, or neo-transduced
marrow. This reduction in cell number was seen as early as
11 days posttransplant and persisted through the duration of
the study. The reduction in cellularity correlated with levels
of IL-2, with the MSCV-neo, Jzen-mIL2, 50% MSCV-
mIL2, and 100% MSCV-mIL2 groups showing progressive-
ly reduced cellularity compared with control marrow or
spleen numbers. For marrow, mice transplanted with 100%
Table 2. IL-2 serum levels in mice transplanted with transduced bone marrow
Day
Test group 14 20 50 100
Control 32 6 6 30 6 8 32 6 3 34 6 4
MSCV-mIL2.PGK-neo (100%) 620 6 23 320 6 16 ND ND
MSCV-mIL2.PGK-neo (50%) 500 6 25 140 6 11 ND ND
Jzen-mIL2.TK-neo 58 6 5 60 6 9 53 6 3 55 6 4
MSCV.PGK-neo 35 6 3 38 6 3 50 6 7 30 6 4
Serum levels (pg/mL) of IL-2 were measured in C57BL/6 mice transplanted
with untransduced (control) marrow or marrow transduced with MSCV-
mIL2.PGK-neo (100 or 50%), Jzen-mIL2.TK-neo, and MSCV.PGK-neo
retroviruses on days 14, 20, 50, and 100 posttransplantation. Blood was col-
lected from mice by cardiac puncture, and serum was collected by centrifuga-
tion. Serum was stored at –20°C until all samples were collected. IL-2 levels
were assayed by ELISA.
Figure 4. Survival of C57BL/6 mice transplanted with retrovirally
transduced BM
Lethally irradiated C57BL/6 mice were transplanted with syngeneic bone
marrow that had been retrovirally transduced by coculture with retroviral
producer cells. Mice were monitored for survival after transplantation. Mice
were transplanted with either control untransduced (black diamonds) marrow
or BM that had been transduced with MSCV-mIL2.PGK-neo (100% shown
with white squares and 50% shown with white diamonds), Jzen-mIL2.TK-
neo (white triangles), or MSCV-neo (transduced control, white circles). Both
groups transplanted with MSCV-mIL2.PGK-neo had 100% mortality with-
in 30 days with average and median survivals of 21.7 and 23 days and 25.3
and 28 days for groups transplanted with 100% and 50% transfected mar-
row, respectively. Mice transplanted with Jzen-mIL2.TK-neo transduced
marrow had a 66% survival over 100 days. Both control transduced and
untransduced mice had 100% survival over the 100-day duration of this
study.
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MSCV-mIL2–transduced marrow exhibited a 65–80%
reduction in marrow cellularity during the first 2 weeks
posttransplant, whereas those transplanted with 50%
MSCV-mIL2 had a 70% reduction and Jzen-mIL2–trans-
planted mice had a 25–40% reduction over the same period
(25–50% reduction over 100 days posttransplant). A similar
trend was seen in the spleen, although to a lesser extent. For
spleen cellularity, 100% MSCV-mIL2–transplanted animals
had a 40–50% reduction in cellularity, those transplanted
with 50% MSCV-mIL2 had a 40% reduction, and those
transplanted with Jzen-mIL2 showed a 10–30% reduction
over the first 14 days posttransplant (10–75% reduction
over 100 days posttransplant). The cellularity of mice trans-
planted with control transduced marrow was similar to that
of mice transplanted with untransduced marrow (97–120%
of control marrow and 78–110% of control spleen). Regres-
sion and variance analyses were performed to determine if a
causal relationship existed between IL-2 levels and BM and
spleen cellularity. IL-2 levels were found to have a signifi-
cant effect on BM cellularity (r2 = 0.66, p = 0.002), but an
effect of IL-2 levels on spleen cellularity could not be
demonstrated (r2 = 0.23, p = 0.13). These data suggested that
IL-2 transduction adversely effected engraftment and recon-
stitution of the hematopoietic system by directly affecting
progenitor cells or by inhibiting their ability to properly
engraft and reconstitute the hematopoietic system. 
In an attempt to evaluate this mechanism, the number
of progenitor cells in transplanted mice was determined
using a colony-forming cell assay. These experiments
demonstrated that mice transplanted with IL-2–transfected
marrow also exhibited a reduction in the number of pro-
genitor cells in their marrow (Fig. 6A). Marrow from trans-
planted mice was collected at days 14, 50, and 100 and ana-
lyzed in a CFU assay. The number of myeloid progenitors
was also inversely correlated with IL-2 production. On day
14, the CFU output of mice transplanted with 100%
MSCV-mIL2 was 7% of control, that of mice transplanted
with 50% MSCV-mIL2 was 70%, that of mice transplanted
with Jzen-mIL2 was 90%, and that of mice transplanted
with MSCV-neo was 100%. Clonogenic output for the
Jzen-mIL2 group ranged from 10 to 50% of control over
100 days posttransplant, and control neo transduced ranged
from 50 to 100%. Not surprisingly, the percentage of trans-
duced clonogenic cells in the transplanted marrow declined
over time. For the MSCV-mIL2–transplanted mice, the
percentage of transduced cells in the marrow declined from
74% (pretransplant) to undetectable levels by day 14
(because of low colony number) whereas that of Jzen-trans-
planted mice declined from 11% pretransplant to 1% by day
14 and 0% by day 40 (also because of low colony number).
The percentage declined more slowly with control trans-
fected marrow (25% pretransplant to 17% day 40). 
Analyzing progenitor cells using a CFU-S assay also
indicated a reduction in progenitor cells in mice transplant-
ed with IL-2–transduced marrow (Fig. 6B), although the
observed reduction was relatively small. The smaller reduc-
tion may be due to the fact that CFU-S cells represent more
committed progenitors and the two assays therefore each
detect a different population of progenitor cells. Spleens
were excised from transplanted mice on day 12 posttrans-
plantation and examined macroscopically for the presence of
visible colonies on the surface of the organ. Spleens from
mice transplanted with 100% MSCV-mIL2 marrow had a
30% reduction in CFU-S compared with controls. Those
transplanted with 50% MSCV-mIL2–transduced marrow
exhibited a 22.5% reduction, and Jzen-mIL2–transplanted
mice had a 7.5% reduction. 
Regression and variance analyses to evaluate the causal
relationship between IL-2 levels and hematopoietic pro-
genitor cell numbers (CFU and CFU-S) were also per-
formed. Analysis of hematopoietic progenitor cells indicat-
ed a significant relationship between IL-2 levels and CFU
and CFU-S (r2 = 0.49, p = 0.02 and r2 = 0.91, p = 0.01,
respectively).
Figure 5. Cellularity of bone marrow and spleen in mice trans-
planted with retrovirally transduced bone marrow
Bone marrow and spleen were collected from C57BL/6 mice 11, 14, 50, and
100 days posttransplantation with retrovirally transduced marrow. Spleen was
dissociated into single cells by passing through a cell sieve. Erythrocytes were
lysed and nucleated cells from the marrow (A) and spleen (B) were counted by
trypan blue exclusion using a hemacytometer. Marrow and spleen were isolated
from mice transplanted with MSCV-mIL2.PGK-neo (100%, cross-hatched
bars; 50%, stippled bars), Jzen-mIL2.TK-neo (white bars), or MSCV.PGK-
neo (black bars) transduced marrow. Results are expressed as a percentage of cell
numbers found in mice transplanted with control, untransduced marrow. A:
Mice transplanted with MSCV-mIL2.PGK-neo showed dramatically reduced
marrow cellularity (75–80 and 70% reduction from control in mice trans-
planted with 100 and 50% transduced marrow, respectively, 14 days post-
transplantation). Mice transplanted with Jzen-mIL2.TK-neo transduced mar-
row had a 25–40% reduction within the first 14 days and 25–50% reduction
over 100 days posttransplantation. Transduction with MSCV-PGK-neo retro-
viruses had no significant effect (98–120% of control). B: Mice transplanted
with MSCV-mIL2.PGK-neo also showed reduced splenic cellularity (50%
reduction when transplanted with 100% transduced marrow and 40% reduc-
tion with 50% transduced marrow) 14 days posttransplantation. Within the
same time period, Jzen-mIL2.TK-neo transplanted mice had a 10–30%
reduction in cellularity with a 10–75% reduction by 100 days posttransplant.
Control transduced marrow ranged from 80 to 110%. 
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Antileukemic effect of BM transduced with 
the cDNA for IL-2
In spite of the adverse effects of IL-2 transduction on
hematopoietic reconstitution, we were able to achieve long-
term survival of mice transplanted with BM retrovirally
transduced with mIL-2, albeit only in mice transplanted
with the relatively low titer, low IL-2–producing Jzen-mIL2
retrovirus, suggesting that only low levels of IL-2 transgene
expression would allow survival. To determine if production
of a low level of the immunomodulatory cytokine in the
bone marrow was able to exert an antileukemic effect, we
challenged transplanted mice with the leukemic cell line
MMB3.19 (Fig. 7). Control mice transplanted with either
untransduced or neo-transduced marrow suffered 100%
mortality within 70 days, with an average and median sur-
vival of 47 and 50 days, respectively, for untransduced con-
trol marrow and 50 and 52 days, respectively, for neo-trans-
duced control marrow. These data suggest that retroviral
transduction did not influence the progression or outcome
of the disease as indicated by the similar survival parameters
of control transduced and untransduced animals. The aver-
age and median length of survival of mice in both groups
was longer than expected based on preliminary experiments
showing that a challenge of 104 leukemic cells resulted in an
average survival of 24 days and median survival of 23.5 days,
probably because of a change in the source of the animals.
As expected, all mice transplanted with MSCV-
mIL2–transduced marrow and challenged with MMB3.19
cells died within 30 days. Mice transplanted with 100%
MSCV-mIL2–transduced BM had an average life span of
23.8 days and a median survival of 24 days. Those trans-
planted with 50% transduced marrow had an average sur-
vival of 27 days; the median survival also was 27 days. These
results are practically identical to those seen in lethally irra-
diated mice transplanted with 50 or 100% MSCV-mIL2
transduced marrow but not challenged with the leukemic
cells, indicating that the mice in these groups died as a result
of graft failure, as seen in these earlier experiments, as
opposed to an effect of the leukemic challenge. 
Of particular interest in this study is that mice trans-
planted with Jzen-mIL2–transduced marrow and challenged
Figure 6. Progenitor cell assays in C57BL/6 mice transplanted with
retrovirally transduced BM
To determine the effect of retroviral transfection on progenitor cell frequency,
mice transplanted with control untransduced marrow were compared with
animals transplanted with 100% (cross-hatched bars) and 50% (stippled
bars) MSCV-mIL2.PGK-neo–transduced marrow, Jzen-mIL2.TK-
neo–transduced marrow (white bars), and MSCV.PGK-neo–transduced mar-
row (transfected control, black bars) using marrow CFU and CFU-S pro-
genitor assays. (A) BM from transplanted mice were isolated on days 14, 50,
and 100 after transplantation and plated in replicates in methycellulose at
concentrations of 2 and 10 x 103. Colonies were counted 15 days later under
an inverted phase-contrast microscope and scored for colony type. Hemato-
poietic progenitors were reduced by 90% and 30% in mice transplanted with
100% and 50% MSCV-mIL2.PGK-neo–transduced marrow, respectively.
Jzen-mIL2.TK-neo–transduced marrow had a 10% reduction, and
MSCV.PGK-neo had no appreciable effect. Although retroviral transduction
did influence progenitor number, it did not affect the ratio of colony types, with
the relative proportions remaining constant in all groups. (B) Spleens were
removed from mice transplanted with retrovirally transduced marrow and
examined for the presence of macroscopic CFU-S colonies on day 12 posttrans-
plantation. Mice transplanted with 100% MSCV-mIL2.PGK-neo–trans-
duced marrow showed a 30% reduction compared with controls, whereas those
transplanted with 50% showed a 15% reduction. CFU-S numbers in Jzen-
mIL2.TK-neo–transplanted mice were 90% those of controls. 
Figure 7. Survival of C57BL/6 mice transplanted with retrovirally
transduced BM and challenged with the MMB3.19 leukemic cell
line
C57BL/6 mice were lethally irradiated, transplanted with either untrans-
duced or retrovirally transduced marrow, challenged with 1 x 104 MMB3.19
leukemic cells, and monitored for survival over 175 days. All mice transplant-
ed with control, untransduced marrow and not challenged (large white dia-
monds) with the leukemic cells survived the full length of the study. Mice
transplanted with control, untransduced marrow (black diamonds) and con-
trol, MSCV.PGK-neo–transduced marrow (black circles) and challenged with
MMB3.19 cells suffered 100% mortality within 70 days, with an average
survival of 47 days and a median of 50 days for the untransfected marrow
and 50 and 52 days for the neo-transduced marrow. Mice transplanted with
either 100% (white squares) or 50% (small white diamonds) MSCV-
mIL2.PGK-neo–transduced marrow and challenged with the MMB3.19 cells
had mean and median survivals of 23.8 days and 24 days for the 100% group
and 27 days for both average and median for the 50% group. Mice trans-
planted with Jzen-mIL2.TK-neo–transduced marrow (black triangles) and
challenged with 104 MMB3.19 cells showed enhanced survival over all other
groups challenged with the leukemic cells. These animals had a 50% survival
rate over the 175 days of the study. 
Antileukemic Effect of IL-2–Transduced Autologous Marrow
239B B & M T
with the MMB3.19 cells exhibited enhanced survival. Mice
in this group had an overall survival rate of 50% over the
175-day duration of this study, only slightly less than the
survival rate seen with mice transplanted with Jzen-
mIL2–transduced marrow alone and greatly enhanced over
the survival seen with control animals (transplanted with
untransduced or neo-transduced marrow) after a leukemic
challenge with the MMB3.19 cells. These data suggest that
low-level production of IL-2 in the marrow resulting from
retroviral gene transfer may be effective in exerting an
antileukemic effect in spite of adverse effects on hemato-
poietic engraftment. This would seem to indicate that if the
adverse effects of IL-2 transduction are sufficiently low to
allow reconstitution of the hematopoietic system and sur-
vival, then the local production of IL-2 in the marrow is
able to exert an antileukemic effect. 
DISCUSSION
High-dose chemotherapy supported by SCT has
improved outcome for people suffering from a number of
hematologic malignancies [1,2]. Autologous SCT eliminates
several of the problems associated with allogeneic SCT,
including availability of a compatible donor and immuno-
logic complications such as GVHD [8–11], and therefore
effectively increases the number of patients able to receive
this therapy. As a result, autologous SCT would be the
treatment of choice if the high relapse rates could be
reduced. We used a murine model to test the possibility of
transferring the gene for the immunomodulatory cytokine
IL-2 to BM cells and using this marrow to reconstitute mye-
loablated syngeneic recipients. Furthermore, we investigat-
ed whether the transplantation of these genetically modified
stem cells has an antileukemic effect, with the aim of using
this approach to reduce the rate of relapse from minimal
residual disease after autologous SCT.
One strategy to reduce relapse is to induce GVT-like
effects through administration of antitumor cytokines such as
IL-2 [19] and IFN-g [18]. A number of studies have exam-
ined whether IL-2 therapy, with SCT, can effectively elimi-
nate residual malignant cells. The strategies include ex vivo
activation of the graft before reinfusion [24,25], infusion with
low- or high-dose IL-2 after transplantation [26,27], or a
combination of both [28,29]. Many studies have reported
that IL-2 can exert anticancer effects through stimulation of
T lymphocytes, activation of NK cells, or induction of sec-
ondary cytokines (i.e., IFN-g and TNF-a). Of particular rel-
evance to this work is a report of specific expansion of
NK/LAK cells in patients given prolonged low doses of IL-2
with no consistent effect on T lymphocytes [30]. 
Unfortunately, systemic administration of cytokines has
several drawbacks, including substantial side effects, particu-
larly when the cytokines are given in the first few weeks
after SCT. Therefore, we have developed a model for the
localized delivery of cytokines to the marrow by trans-
planting stem cells transduced with a cytokine gene. Using
this approach, we hoped to evaluate whether delivery of
cytokines to the marrow could be effective in inducing
antileukemic effects and reducing relapse after autologous
SCT. This work is a follow-up to studies previously per-
formed in our laboratory examining the feasibility of trans-
planting BM transduced with TNF-a [31]. Transfer of
cytokines to autologous hematopoietic (tumor-infiltrating
lymphocytes) [32] and tumor [33] cells has already been
shown in a number of other systems. Injection into tumor-
bearing animals often resulted in regression of the primary
tumor because of upregulation of the major histocompatibil-
ity complex and tumor-specific antigens and local activation
of cytotoxic cells
In the work described here, we demonstrated the feasibil-
ity of introducing cytokine genes to BM cells. Relatively high
levels of gene transfer were seen, and transfer efficiencies and
protein synthesis depended on the retroviral vector used.
Higher titers, transfer efficiencies, and transgene expression
were achieved with the MSCV-based vector than with Jzen
vectors, consistent with work reporting high-efficiency gene
transfer and expression using MSCV-based vectors [34,35].
IL-2 transduction did not have any direct effect on hemato-
poietic progenitors, as judged by clonogenic assays. 
High levels of IL-2 production were achieved in mice
transplanted with the transduced cells, with detectable levels
in the serum. The highest levels were expected to be in the
BM because transduced cells would home to the marrow
cavity of myeloablated recipients. This premise is supported
by earlier work in our laboratory involving transplantation
of marrow transduced with a Jzen vector containing TNF-a
cDNA, in which transgene message and protein expression
were detected in the marrow with no evidence in the serum
of transplanted mice [31]. Furthermore, transduced cells did
home to the marrow of transplanted mice, an observation
that was also supported by this previous work. Elevated
serum IL-2 levels in transplanted animals were probably
caused by high IL-2 expression in both the transduced cells
in the marrow and progeny cells in the peripheral circula-
tion derived from transduced progenitor cells.
IL-2 expression in animals transplanted with MSCV-
mIL2–transduced marrow was initially high and declined
rapidly, whereas those transplanted with Jzen-mIL2–trans-
duced marrow had sustained, low-level transgene expression
for as long as 100 days posttransplant. This would suggest
that at least some early progenitors had been transduced.
Although we could not exclude the possibility that sustained
expression was caused by expression from long-lived circulat-
ing lymphoid cells, we were unable to document clonogenic
lymphoid cells that had been transduced with the IL-2 retro-
viruses or sustained IL-2 expression in transduced marrow
cultured in vitro under conditions favoring lymphoid cells. 
High levels of IL-2 expression reduced the life span of
transplanted animals. The data presented here suggest that
this was a result of impaired hematopoietic engraftment.
Marrow, spleen, and peripheral blood cellularity were
reduced in a dose-dependent manner in mice transplanted
with IL-2–transduced marrow, but no effect was noted with
control vectors. Reduced life span as a result of systemic IL-
2 toxicity also could not be discounted. However, post-
mortem examination did not reveal any gross signs of toxici-
ty, and life span was not correlated with IL-2 levels, as
would be expected in the presence of systemic toxicity (i.e.,
transplanted animals exhibited similar average and median
life spans in spite of substantial differences in IL-2 levels). 
The effect of IL-2 transduction on hematopoiesis
appeared to be a direct influence on the number of pro-
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genitor cells in the transplanted mice, because animals dis-
played an IL-2–dose dependent reduction in clonogenic
progenitor cells. These data taken together suggest that
although IL-2 transduction did not directly influence the
hematopoietic progenitor cells, it did influence either the
ability of these cells to engraft or the ability of accessory
cells (i.e., BM stroma) to support engraftment. The latter
hypothesis is supported by the observed toxicity of the IL-
2–transduced marrow to stromal cells in LTCs and is in
agreement with observations in which IL-2 added to LTCs
within the first 72 hours abolished the fibroblastic compo-
nent of the stromal layer through inhibition of accessory
cells [36].
Numerous studies in both humans and animals have
examined the effect of IL-2 on hematopoietic progenitors,
transplantation, and engraftment and have reported incon-
sistent results. Ettinghausen et al. [37] and Rosenberg et al.
[38] both reported overall suppression of hematopoiesis in
patients undergoing IL-2 therapy. This was supported by
observations of both direct [39] and indirect [40,41] IL-
2–mediated inhibition of hematopoietic progenitors. In
contrast, other studies have reported that culturing of
autologous stem cells with or without infusion of IL-2 after
transplantation did not affect stem cell number or engraft-
ment [42–44], and some researchers have even reported
enhanced hematopoiesis [45–47]. Certainly, IL-2 has been
shown to play a role in the regulation of hematopoietic dif-
ferentiation under a number of circumstances [48,49]. The
basis for these contradictory results is unclear, although dif-
ferences in a number of factors—including treatment regi-
men, dose, and timing—may account for some of the dis-
parate results.
In spite of the adverse effect of high IL-2 expression on
hematopoietic reconstitution reported here, the data
described suggest that delivery of IL-2 to the marrow can
exert an antileukemic effect. Mice transplanted with IL-
2–transduced marrow show a significantly increased average
and median life span after a challenge with AML cells com-
pared with mice transplanted with untransduced or trans-
duced control marrow. Although the mechanism for this
antileukemic effect is unclear, evidence exists from other
studies that IL-2 therapy mediates its effects by enhancing
the activity of autologous cytotoxic cells against malignant
cells. This is consistent with data showing that splenocytes
and BM cells from mice transplanted with Jzen-mIL-
2–transduced marrow have increased antileukemic cytotoxi-
city [50] and that MMB3.19 cells are sensitive to LAK cell
cytolysis. Another possibility is that IL-2 impairs the ability
of the malignant cells to home to the marrow or to establish
themselves once there. 
In view of our results and those reported for IL-2
immunotherapy, a number of parameters may be critically
important to the efficacy of this strategy and must be careful-
ly considered and evaluated on the basis of hematopoietic
and antileukemic effects. These include the identity of the
cytokine, the level of cytokines produced in the marrow, the
time during hematopoietic reconstitution when exposure
occurs, the length of exposure, or a combination of these fac-
tors. At this point, the relative contribution of these factors
in modulating the effects of cytokines on hematopoiesis is
not clear. The contributions of these factors need to be con-
sidered to minimize the adverse effects of these cytokines on
hematopoietic engraftment and reconstitution while maxi-
mizing the beneficial antileukemic effects. When these fac-
tors are evaluated, modification of this strategy through the
use of a different cytokine or cytokines and vectors that can
be regulated to control expression can be considered. 
The results of these preliminary studies support the
potential use of autologous hematopoietic progenitor cells
as vehicles for delivery of cytokines to the marrow. Deliver-
ing antileukemic cytokines while minimizing the toxicity
associated with systemic administration may provide an
effective adjuvant treatment to myeloablative therapy and
autologous SCT. Using this strategy, it may be possible to
control or eliminate residual disease and reduce relapse in
leukemia and other malignancies in which residual cancer
cells may persist after therapy. 
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